SPRC
Price:
$0.2212
Market Cap:
$2.29M
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and...[Read more]
Industry
Biotechnology
IPO Date
2021-08-30
Stock Exchange
NASDAQ
Ticker
SPRC
According to SciSparc Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is -0.04. This represents a change of -23.61% compared to the average of -0.05 of the last 4 quarters.
The mean historical PE Ratio of SciSparc Ltd. over the last ten years is -681.33. The current -0.04 PE Ratio has changed -99.41% with respect to the historical average. Over the past ten years (40 quarters), SPRC's PE Ratio was at its highest in in the December 2022 quarter at 0.36. The PE Ratio was at its lowest in in the June 2016 quarter at -1975.37.
Average
-681.33
Median
-126.69
Minimum
-2201.94
Maximum
-0.34
Discovering the peaks and valleys of SciSparc Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 99.63%
Maximum Annual PE Ratio = -0.34
Minimum Annual Increase = -105.07%
Minimum Annual PE Ratio = -2201.94
Year | PE Ratio | Change |
---|---|---|
2023 | -0.34 | -74.66% |
2022 | -1.33 | -39.35% |
2021 | -2.20 | -95.38% |
2020 | -47.61 | -66.94% |
2019 | -144.01 | 31.66% |
2018 | -109.38 | -95.00% |
2017 | -2187.53 | -0.65% |
2016 | -2201.94 | 99.63% |
2015 | -1103.00 | 8.56% |
2014 | -1015.99 | -105.07% |
The current PE Ratio of SciSparc Ltd. (SPRC) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.29
5-year avg
-39.10
10-year avg
-681.33
SciSparc Ltd.’s PE Ratio is less than OncoSec Medical Incorporated (-0.01), greater than Virax Biolabs Group Limited (-0.57), greater than Hillstream BioPharma, Inc. (-0.99), less than ZyVersa Therapeutics, Inc. (-0.00), greater than Unicycive Therapeutics, Inc. (-2.06), greater than Quoin Pharmaceuticals, Ltd. (-0.28), greater than Cardio Diagnostics Holdings, Inc. (-2.99), less than PaxMedica, Inc. Common Stock (-0.03), greater than YS Biopharma Co., Ltd. (-0.80), greater than Cadrenal Therapeutics, Inc. Common Stock (-2.14), greater than Virios Therapeutics, Inc. (-0.76), greater than Hoth Therapeutics, Inc. (-0.72), greater than Neoleukin Therapeutics, Inc. (-5.86), less than CytomX Therapeutics, Inc. (6.58), greater than Assembly Biosciences, Inc. (-2.29), greater than Instil Bio, Inc. (-1.89), greater than Nuvation Bio Inc. (-1.45), less than Blue Water Vaccines, Inc. (-0.01), greater than Revelation Biosciences, Inc. (-0.05), less than Kiora Pharmaceuticals, Inc. (2.50),
Company | PE Ratio | Market cap |
---|---|---|
-0.01 | $1.65M | |
-0.57 | $7.47M | |
-0.99 | $4.17M | |
-0.00 | $2.70M | |
-2.06 | $69.56M | |
-0.28 | $2.45M | |
-2.99 | $40.84M | |
-0.03 | $696.27K | |
-0.80 | $192.09M | |
-2.14 | $24.50M | |
-0.76 | $206.50K | |
-0.72 | $5.43M | |
-5.86 | $8.20M | |
6.58 | $83.74M | |
-2.29 | $93.56M | |
-1.89 | $142.85M | |
-1.45 | $949.12M | |
-0.01 | $3.41M | |
-0.05 | $2.51M | |
2.50 | $9.87M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like SciSparc Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like SciSparc Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is SciSparc Ltd.'s PE Ratio?
How is the PE Ratio calculated for SciSparc Ltd. (SPRC)?
What is the highest PE Ratio for SciSparc Ltd. (SPRC)?
What is the 3-year average PE Ratio for SciSparc Ltd. (SPRC)?
What is the 5-year average PE Ratio for SciSparc Ltd. (SPRC)?
How does the current PE Ratio for SciSparc Ltd. (SPRC) compare to its historical average?